# Lingbo Biology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lingbo-biology

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.leadbio.com
- Total disclosed funding: $15M
- Latest round: Series A (Jun 14, 2024)
- Investors on record: 6

## About

Based in Hangzhou, China, and established in 2019, Lingbo Biology is a medical equipment manufacturing company that focuses on the development and production of bio-based artificial blood vessel medical devices. Deling Kong, the founder of the company, is a professor in the College of Life Sciences of Nankai University and the director of the International Society of Blood Purification. In 2019, the company participated in the China Medical Device Innovation and Entrepreneurship Competition. In June 2024, Lingbo Biology closed a series A+ funding.

The company's main business is the research and development of regenerative repair materials and regenerative artificial organs. Products can be categorized into artificial blood vessels, artificial esophagus, and vascular patches. The specification of its artificial blood vessel products surpassed 6mm caliber. At present, the company has built 3 major technology platforms, which are decellularized matrix, 3D printing, and hydrogel. It also developed technology for polymer decellularization bonding. The products mainly serve patients with heart bypass, hemodialysis, peripheral vascular, and other diseases.

The company generates revenue by providing regenerative repair materials and regenerative artificial organs.

The company will use the series A+ funding for product clinical research, the development of artificial blood vessels for new indications of cardiac bypass grafting, and market expansion.

## Funding rounds

- Series A, Jun 14, 2024 — Tasly Capital
- Series A, Nov 13, 2023, $14M — Panlin Capital, Insight Capital, TigerYeah Capital, BGI Co-WIN Investment Management, Tailong VC
- Angel, Jun 9, 2020, $1.4M — TigerYeah Capital

## Investors

- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Angel, Series A
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A
- Insight Capital — Series A
- BGI Co-WIN Investment Management (https://capitalatlas.ai/funds/bgi-co-win-investment-management) — Series A
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series A
- Tasly Capital — Series A